Novel compounds

Abstract

The invention is directed to methods of treatment using compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.

1 - 12 . (canceled) 
     
     
         13 . A method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering a compound of formula (I): 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is 9- or 10-membered bicyclic heteroaryl wherein the 9- or 10-membered bicyclic heteroaryl contains from one to three heteroatoms independently selected from oxygen and nitrogen and is optionally substituted by C 1-6 alkyl, C 3-6 cycloalkyl, halo, —CN or —NHSO 2 R 5 , or 
         pyridinyl optionally substituted by one or two substituents independently selected from C 1-6 alkyl, —OR 6 , halo and —NHSO 2 R 7 ; 
         R 2  and R 3 , together with the nitrogen atom to which they are attached, are linked to form a 6- or 7-membered heterocyclyl wherein the 6- or 7-membered heterocyclyl optionally contains an oxygen atom or a further nitrogen atom and is optionally substituted by one or two substituents independently selected from C 1-6 alkyl; 
         R 4  is hydrogen or methyl; 
         R 6  is hydrogen or C 1-4 alkyl; and 
         R 5  and R 7  are each independently C 1-6 alkyl, or phenyl optionally substituted by one or two substituents independently selected from halo; 
         or a salt thereof, to a patient having said disorder. 
       
     
     
         14 . The method according to  claim 13 , wherein R 1  is
 9-membered bicyclic heteroaryl wherein the 9-membered bicyclic heteroaryl contains one or two nitrogen atoms, or pyridinyl optionally substituted by one or two substituents independently selected from —OR 6  and —NHSO 2 R 7 .   
     
     
         15 . A method according to  claim 13 , wherein R 1  is indolyl. 
     
     
         16 . A method according to  claim 13 , wherein R 1  is pyridinyl optionally substituted by one or two substituents independently selected from —OR 6  and —NHSO 2 R 7 . 
     
     
         17 . A method according to  claim 13 , wherein R 2  and R 3 ,
 together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocyclyl wherein the 6-membered heterocyclyl optionally contains an oxygen atom or a further nitrogen atom and is optionally substituted by one or two substituents independently selected from C 1-6 alkyl.   
     
     
         18 . A method according to  claim 13 , wherein R 2  and R 3 , together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocyclyl wherein the 6-membered heterocyclyl contains an oxygen atom and is optionally substituted by one or two substituents independently selected from C 1-4 alkyl. 
     
     
         19 . A method according to  claim 13 , wherein R 2  and R 3 , together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocyclyl wherein the 6-membered heterocyclyl contains a further nitrogen atom and is optionally substituted by C 1-4 alkyl. 
     
     
         20 . A method according to  claim 13 , wherein R 4  is hydrogen. 
     
     
         21 . A method according to  claim 13  wherein the compound of formula (I) is in the form of a pharmaceutically acceptable salt thereof. 
     
     
         22 . A method according to  claim 13  wherein the disorder mediated by inappropriate PI3-kinase activity is a respiratory disease, a viral infection, a non-viral respiratory infection, an allergic disease, an autoimmune disease, an inflammatory disorder, a cardiovascular disease, a hematologic malignancy, a neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, or pain. 
     
     
         23 . A method according to  claim 13  wherein the disorder mediated by inappropriate PI3-kinase activity is asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia or Central pain. 
     
     
         24 . A method according to  claim 13 , wherein the disorder mediated by inappropriate PI3-kinase activity is asthma. 
     
     
         25 . A method according to  claim 13 , wherein the disorder mediated by inappropriate PI3-kinase activity is chronic obstructive pulmonary disease (COPD).